Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cobimetinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ACTR3 | P61158 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cobimetinib SCHEMBL188704 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL29839406 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL189565 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL1488831 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL29413366 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL29413464 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL30220897 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL1489148 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| Cobimetinib SCHEMBL1488436 | 0.99 | MAP2K1 (0.98) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488014 | 0.97 | MAP2K1 (0.95) | MAP2K1MAP2K2CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317264-B1 | CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE | EXELIXIS INC (US) | 2025-09-10 | — | — | EP | claimed |
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| CN-118290395-A | Crystalline fumarate salt | 埃克塞里艾克西斯公司 | 2024-07-05 | — | — | CN | claimed |
| CN-116847875-A | Active cancer immunotherapy by immunomodulation via GLOBO series antigens | 台湾浩鼎生技股份有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116159140-A | Use of MAPK pathway inhibitors against pathogen infection | 中国科学院上海巴斯德研究所 | 2023-05-26 | — | — | CN | claimed |
| EP-3370775-B1 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2023-04-19 | — | — | EP | claimed |
| WO-2023044386-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2023-03-23 | — | — | WO | claimed |
| EP-3702445-B1 | NOVEL MUSCULOSKELETAL STEM CELL | CELLATOZ THERAPEUTICS INC (KR) | 2022-12-07 | — | — | EP | claimed |
| EP-4097259-A1 | METHODS FOR IMPROVED CANCER TREATMENT | Cellphenomics GmbH (DE) | 2022-12-07 | — | — | EP | claimed |
| US-11395823-B2 | Topical administration of MEK inhibiting agents for the treatment of skin disorders | DUKE UNIVERSITY (US) | 2022-07-26 | — | — | US | claimed |
| US-20220056010-A1 | CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE | EXELIXIS INC (US) | 2022-02-24 | — | — | US | claimed |
| US-11254649-B2 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | EXELIXIS, INC. (US) | 2022-02-22 | — | — | US | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056010-A1 | CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE | FH, MFAP1, MSH2 | MAP2K1 2556/4885MAP2K2 2718/4885CHRM2 4688/4885 |
| US-11254649-B2 | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone | FH, SDHA, SDHB | MAP2K1 2600/4885MAP2K2 2837/4885CHRM2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.